Three years ago, Johnson & Johnson ($JNJ) pulled Rolaids antacid products off the market, on fears that wood and metal particles had made their way into the tablets. Now, Sanofi's ($SNY) Chattem unit has brought the brand back to life, with tablet and liquid versions. The consumer health unit bought Rolaids rights from J&J earlier this year. Report